Study | No. screened | SUAC cut-off | 2×2 table | Sensitivity% (95% CI) | Specificity% (95% CI) | PPV% (95% CI) | NPV% (95% CI) | |||
---|---|---|---|---|---|---|---|---|---|---|
TP | TN | FP | FN | |||||||
Studies reporting screening experiences | ||||||||||
La Marca [17] | 136,075 [Overlap of 13,000 with [22]] | 2 μmol/l | 2 | NA | 0 | NA | NA | NA | 100 (19.8-100) | NA |
Lund [18] | 140,565 | 2.1 U | 1 | NA | 0 | NA | NA | NA | 100 (5.5-100) | NA |
Morrissey [12] | ~500,000 | 3 μmol/l | 2 | NA | 1 | NA | NA | NA | 66.7 (12.5-98.2) | NA |
Sander [19] | 61,344 | ≥10 μmol/l | 2 | NA | 0 | NA | NA | NA | 100 (19.8-100) | NA |
Zytkovicz [20] | 518,687: 515,592 newborns, 3095 over 1 month old | >4 μM (recently reduced to 3.3 μM) positive; SUAC 1.0-3.3 μM intermediate | 3 | NA | 0 | NA | NA | NA | 100 (31.0-100) | NA |
Case–control studies | ||||||||||
Allard [14] | 4,002: 3 cases, 3,199 controls | 2 μmol/l | 3 | 3199 | 0 | 0 | 100 (31.0-100) | 100 (99.85-100) | N/A | N/A |
Dhillon [21] | >1,026: 6 cases, >1,000 controls | 3 μmol/l | 6 | >1,000 | 0 | 0 | 100 (51.7-100) | N/A | N/A | N/A |
La Marca [22] | 13,006: 6 cases, 13,000 controls [Overlap with la Marca [17]] | 2.4 μmol/l | 6 | 13,000 | 0 | 0 | 100 (51.7-100) | 100 (99.96-100) | N/A | N/A |
Metz [23] | 4686: 3 cases, 4683 controls | 1.29 μmol/l | 3 | 4683 | 0 | 0 | 100 (30.9-100) | 100 (99.90 – 100) | N/A | N/A |
Turgeon [24] | 13,532: 11 cases, 13,521 controls. | >5 μmol/l | 11 | 13,521 | 0 | 0 | 100 (67.9-100) | 100 (99.96-100) | N/A | N/A |